Semaglutide vs Tirzepatide vs Retatrutide
Semaglutide
Approved and widely used in China, with the most mature data.
Indications
- Type 2 diabetes patients
- Poor blood glucose control; can be used alone or with other antidiabetic drugs.
- Overweight / obese adults
- BMI ≥ 24 kg/m² with at least one weight-related condition (hypertension, hyperlipidemia, fatty liver, etc.)
- OR BMI ≥ 28 kg/m²
Features
- Moderately strong blood glucose lowering and weight loss effects
- Most extensive safety data
- Covered by medical insurance (for diabetes indication only)
Tirzepatide
GIP+GLP‑1 dual agonist; stronger than semaglutide.
Indications
- Type 2 diabetes patients
- Better glucose control than semaglutide.
- Overweight / obese adults
- Significantly greater weight loss than semaglutide.
- Suitable for those wanting more weight reduction.
Features
- Strong effects on both glucose control and weight loss
- Side effects (nausea, diarrhea) may be more noticeable
- Approved and available in China
Retatrutide
GLP‑1/GIP/GCG triple agonist; currently the most potent class.
Important notes
- Not yet approved in China
- Only used in clinical trials or certain regions abroad
Theoretical indications
- Type 2 diabetes
- Obesity / severe obesity
- Strongest weight loss effect among all GLP‑1 agents so far
Features
- Most potent effects, but long-term safety data are still being collected
- Not legally available or prescribable in China
Simple summary
- Safe, stable, insurance-covered → semaglutide
- Stronger glucose control + weight loss → tirzepatide
- Retatrutide: not yet available in China; not recommended to purchase privately
| Item | Semaglutide | Tirzepatide | Retatrutide |
| Class | GLP‑1 receptor agonist | GIP+GLP‑1 dual agonist | GLP‑1/GIP/GCG triple agonist |
| Approved in China | Approved & available | Approved & available | Not approved |
| Main Indications | Type 2 diabetes, weight management | Type 2 diabetes, weight management | Type 2 diabetes, obesity (clinical stage) |
| Glucose control | Strong | Stronger | Strongest (trial data) |
| Weight loss | Strong | Significantly stronger | Strongest so far |
| Suitable for | Diabetes, stable weight loss | Diabetes, larger weight loss goal | Severe obesity (studies abroad) |
| Common side effects | Nausea, bloating, diarrhea, constipation | Nausea, diarrhea, decreased appetite | Nausea, vomiting, diarrhea (may be higher) |
| Insurance | Covered for diabetes | Covered for diabetes | Not covered |
| Availability | Hospitals, licensed pharmacies | Hospitals, licensed pharmacies | Not legally available in China |
| Key points | Safe, well‑established | More potent, reliable data | Most powerful, not approved in China |
Share:
More Posts

Semaglutide vs Tirzepatide vs Teriparatide vs Abaloparatide vs Glycopyrrolate: Peptide API Comparison
Compare Semaglutide, Tirzepatide, Teriparatide, Abaloparatide & Glycopyrrolate peptide APIs: CAS numbers, synthesis routes, patent cliff analysis & global export volume data. For research use only.
SERMs vs Thyroid Hormones: Enclomiphene, Clomiphene, Tamoxifen, T3 & T4 — The Complete Comparison
This article clarifies the critical pharmacological differences between SERMs (Enclomiphene, Clomiphene, Tamoxifen) and thyroid hormones (T3, T4), two commonly confused families of hormone-modulating compounds. Many users mistakenly treat them as interchangeable “hormone optimizers” for stacking or substitution, which carries unnecessary physiological risks. This breakdown compares their molecular structures, receptor targets, and core regulatory pathways: SERMs act on estrogen receptors to modulate the HPG axis and endogenous testosterone output, while T3/T4 bind universal nuclear thyroid receptors to control basal metabolism, thermogenesis, and systemic cellular function. It further distinguishes Clomiphene’s dual-isomer composition from purified Enclomiphene, alongside Tamoxifen’s unique tissue-selective activity. This evidence-based guide eliminates common endocrine misconceptions and defines safe, research-only application boundaries for laboratory reference.
ISRIB A-17 Properties
ISRIB A-17: Properties, Advantages and Exclusive Research Applications Chemical Probes · ISR Pathway ISRIB A-17: Properties, Advantages and Exclusive Research Applications By Research Chemistry Team
CPHI China 2026
CPHI China 2026: NutraBiotech at Asia’s Largest Pharma Exhibition | SNIEC Shanghai Home / Blogs / Industry Events / CPHI China 2026 CPHI China 2026: